Fig. 3

Suppression of IDH2 blocked the conversion of α-KG to isocitrate in reductive TCA cycle. a, b Quantitation of α-KG in U937 or ML-1 cells harboring shRNA-Ctrl, shIDH2#1 or shIDH2#2. c, d Levels of isocitrate in U937 or ML-1 cells harboring shRNA-Ctrl, shIDH2#1 or shIDH2#2. e, f Levels of citrate in U937 or ML-1 cells harboring shRNA-Ctrl, shIDH2#1 or shIDH2#2. g Schematic illustration of changes in α-KG, isocitrate, and citrate in AML cells after suppression of active reductive TCA flow using IDH2 shRNA. h Quantitation of α-KG in tumor tissues from mice bearing U937 xenografts harboring shRNA-Ctrl, shIDH2#1 or shIDH2#2. i, j Comparison of α-KG levels in U937 and ML-1 cells cultured with or without glutamine for 24 h. Gln (+): glutamine 2 mM, Gln (−): glutamine free. n = 3, mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001